Physician profile
Nauman Moazzam
NPI 1407812043
$80,285.33
in general payments reported to CMS, 2019-2025
54 companies · $11K in 2025
The $11K reported for 2025 was more than what 89% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $12K · 2021: $14K · 2022: $13K · 2023: $5,484 · 2024: $5,374 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $4,622 · Travel and Lodging: $1,200 · Honoraria: $375 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,330.00 |
| Food and Beverage | $4,622.43 |
| Travel and Lodging | $1,199.72 |
| Honoraria | $375.00 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $24,384.27 | 2019-2025 | Rybrevant, Erleada, Akeega |
| Astrazeneca Pharmaceuticals Lp | $11,992.51 | 2019-2025 | Imfinzi, Tagrisso, Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $9,475.37 | 2019-2024 | |
| Seagen INC. | $6,206.13 | 2019-2020 | |
| Genzyme Corporation | $6,095.68 | 2021-2025 | |
| Pfizer INC. | $4,092.96 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $3,110.11 | 2019-2025 | |
| Adc Therapeutics America, INC. | $2,000.00 | 2021 | |
| Gilead Sciences, INC. | $1,573.60 | 2019-2025 | Trodelvy |
| Karyopharm Therapeutics INC. | $1,550.00 | 2021 | |
| Aveo Pharmaceuticals, INC. | $1,365.00 | 2023 | Fotivda |
| Array Biopharma INC | $1,260.00 | 2021 | |
| Celgene Corporation | $1,248.70 | 2020-2024 | Reblozyl |
| Taiho Oncology, INC. | $1,130.00 | 2024 | |
| G1 Therapeutics, INC. | $802.12 | 2022-2023 | Cosela |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $725.35 | 2020-2025 | |
| Abbvie INC. | $376.13 | 2024-2025 | |
| Astellas Pharma US INC | $313.88 | 2024-2025 | Vyloy, Padcev, Cresemba |
| Glaxosmithkline, LLC. | $254.93 | 2024-2025 | Ojjaara, Jemperli, Blenrep |
| Daiichi Sankyo INC. | $253.53 | 2024-2025 | Enhertu |
| Intuitive Surgical, INC. | $217.36 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $192.70 | 2023-2025 | Orgovyx |
| Tersera Therapeutics LLC | $168.43 | 2024-2025 | Zoladex, Xermelo |
| E.R. Squibb & Sons, L.L.C. | $118.91 | 2021-2025 | Opdivo, Eliquis |
| Merck Sharp & Dohme LLC | $108.06 | 2020-2025 | Keytruda, Welireg, Keytruda Qlex |
| Ipsen Biopharmaceuticals, INC | $104.98 | 2019-2024 | Onivyde |
| Springworks Therapeutics, INC. | $103.76 | 2025 | Ogsiveo, Gomekli |
| Regeneron Healthcare Solutions, INC. | $98.87 | 2023-2025 | Libtayo |
| Exelixis INC. | $91.60 | 2024-2025 | Cabometyx |
| Iovance Biotherapeutics, INC. | $87.54 | 2024-2025 | Amtagvi |
| Mirati Therapeutics, INC. | $86.23 | 2023-2024 | Krazati |
| Erbe USA INC | $75.00 | 2024 | Vio 3 Cryo2 |
| Kite Pharma, INC. | $71.12 | 2019 | |
| Genmab U.S., INC. | $60.60 | 2024-2025 | Epkinly |
| Stemline Therapeutics INC. | $46.74 | 2023-2025 | Orserdu |
| Incyte Corporation | $46.36 | 2025 | Niktimvo, Jakafi, Monjuvi |
| Alexion Pharmaceuticals, INC. | $36.83 | 2020 | |
| Legend Biotech USA INC. | $33.01 | 2025 | Carvykti |
| Puma Biotechnology, INC. | $33.00 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $28.75 | 2025 | Givlaari |
| Genentech USA, INC. | $26.59 | 2024 | Venclexta |
| Recordati_rare_diseases_inc. | $24.20 | 2025 | Sylvant |
| Azurity Pharmaceuticals, INC. | $22.74 | 2025 | Danziten |
| Pharmacyclics LLC, An Abbvie Company | $21.91 | 2019 | |
| Adaptive Biotechnologies Corporation | $21.07 | 2025 | Clonoseq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.58 | 2025 | |
| Myriad Genetic Laboratories, INC. | $18.22 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.98 | 2024 | Fruzaqla |
| Ferring Pharmaceuticals INC. | $17.76 | 2024 | Adstiladrin |
| Tactile Systems Technology INC | $17.66 | 2024 | Flexitouch Plus, Entre Plus |
| Immunogen, INC. | $16.89 | 2023 | Elahere |
| Nestle Healthcare Nutrition INC. | $15.29 | 2021 | |
| Pharmacosmos Therapeutics INC. | $15.14 | 2025 | Monoferric |
| Clovis Oncology, INC. | $10.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nauman Moazzam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.